Efficacy of Sorafenib for the Treatment of Post-Transplant Hepatocellular Carcinoma Recurrence.

Conclusion: Sorafenib may be beneficial in patients with post-transplant HCC recurrence.
PMID: 30402048 [PubMed - in process]

Source: J Korean Med Sci - November 5, 2018 Category: General Medicine Authors: Kang SH, Cho H, Cho EJ, Lee JH, Yu SJ, Kim YJ, Yi NJ, Lee KW, Suh KS, Yoon JH Tags: J Korean Med Sci Source Type: research